Exemplifying this concept is the fact that chronic exposure to gefitinib, an agent that targets the EGFR, results in emergence of resistant lung cancer cells bearing a mutation in the EGFR that renders these tumoral cells insensitive to the drug [41]. This evidence concerns the gene EGFR and lung carcinoma.